BRTX · BioRestorative Therapies, Inc. · Executive Compensation
$2.24
-0.03 (-1.32%)
At close · Oct 7
Return incl. dividend (before tax)
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“we believe we do not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this Quarterly Report which raises substantial doubt about our ability to continue as a going concern.”View the 10-Q filed May 14, 2026
Market Cap
$2.97M
Shares
1.27M
Volume · Oct 7
38.68K
Avg daily vol (21 sessions)
34.39K
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2024
| Executive | Role | Total |
|---|---|---|
| Lance Alstodt | Chief Executive Officer | $1,314,583 |
| Francisco Silva | VP, Research and Development | $1,227,083 |
| Robert Kristal | Chief Financial Officer | $683,752 |
Fiscal 2023
| Executive | Role | Total |
|---|---|---|
| Lance Alstodt | Chief Executive Officer | $1,254,167 |
| Francisco Silva | VP, Research and Development | $1,204,167 |
| Robert Kristal | Chief Financial Officer | $618,124 |
Fiscal 2022
| Executive | Role | Total |
|---|---|---|
| Lance Alstodt | Chief Executive Officer | $452,364 |
| Francisco Silva | VP, Research and Development | $427,364 |
| Robert Kristal | Chief Financial Officer | $175,000 |
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Lance Alstodt | Chief Executive Officer | $21,341,489 |
| Francisco Silva | VP, Research and Development | $21,325,864 |
| Robert Kristal | Chief Financial Officer | $82,383 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Francisco Silva | VP, Research and Development | $207,553 |
| Mark Weinreb | Chief Executive Officer | $179,172 |
| Lance Alstodt | Chief Executive Officer | $64,317 |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Mark Weinreb | Chief Executive Officer | $372,352 |
| Lance Alstodt | Chief Executive Officer | $350,000 |
| Francisco Silva | VP, Research and Development | $287,500 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Mr. Silva | Vice President of Research and Development | Resigned | 2026-09-11 |
| Anna Skowron | Chief Financial Officer and Treasurer | Appointed | 2026-09-02 |
| Steven Brown | Chairman of the Board | Appointed | 2026-09-02 |
| Mika Grasso | Interim Chief Executive Officer | Appointed | 2026-09-02 |
| Katharyn Field | member of the Board | Resigned | 2026-09-02 |
| Esha Randhawa | Class II director | Appointed | 2026-07-16 |
| Steven Brown | Class III director | Appointed | 2026-07-16 |
| Katharyn Field | interim Chief Financial Officer | Appointed | 2026-07-16 |
| Katharyn Field | Chief Executive Officer and President | Appointed | 2026-07-16 |
| Robert Kristal | Chief Financial Officer | Resigned | 2026-07-16 |
| Lance Alstodt | director | Resigned | 2026-07-16 |
| Lance Alstodt | Chairman of the Board | Resigned | 2026-07-16 |
| Lance Alstodt | President, Chief Executive Officer and Chairman of the Board | Resigned | 2026-07-16 |
| David Rosa | director | Resigned | 2026-07-16 |
| Katharyn Field | director | Appointed | 2026-06-12 |
| Jatinder Dhaliwal | director | Appointed | 2026-06-12 |
| Patrick F. Williams | director | Resigned | 2026-06-12 |
| Mika Grasso | director | Appointed | 2026-06-12 |
| Nickolay Kukekov | director | Resigned | 2026-06-12 |
| Francisco Silva | director | Resigned | 2026-06-12 |